Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
HOOK 
Hookipa Pharma Inc (HOOK)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: HOOK (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
3 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $2
1 Year Target Price $2
| 1 | Strong Buy |
| 0 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -9.01% | Avg. Invested days 32 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 10.85M USD | Price to earnings Ratio - | 1Y Target Price 2 |
Price to earnings Ratio - | 1Y Target Price 2 | ||
Volume (30-day avg) 3 | Beta 1.04 | 52 Weeks Range 0.72 - 4.20 | Updated Date 10/16/2025 |
52 Weeks Range 0.72 - 4.20 | Updated Date 10/16/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -5.85 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -885.28% |
Management Effectiveness
Return on Assets (TTM) -45.2% | Return on Equity (TTM) -105.79% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -28336120 | Price to Sales(TTM) 1.16 |
Enterprise Value -28336120 | Price to Sales(TTM) 1.16 | ||
Enterprise Value to Revenue 1.91 | Enterprise Value to EBITDA 0.46 | Shares Outstanding 9930789 | Shares Floating 9678656 |
Shares Outstanding 9930789 | Shares Floating 9678656 | ||
Percent Insiders 19.02 | Percent Institutions 32.5 |
Upturn AI SWOT
Hookipa Pharma Inc
Company Overview
History and Background
Hookipa Pharma Inc. was founded in 2011. It focuses on developing immunotherapies based on its proprietary arenavirus platform.
Core Business Areas
- VaxWave: A viral vector technology that uses live attenuated arenaviruses to stimulate the immune system. Focuses on infectious diseases
- TheraT: A viral vector technology, which uses attenuated arenaviruses to deliver tumor-associated antigens. Focuses on cancer immunotherapy.
Leadership and Structure
The leadership team consists of experienced executives in the biotechnology and pharmaceutical industries. The organizational structure is typical of a biotech company, focusing on research, development, and clinical trials.
Top Products and Market Share
Key Offerings
- HB-101: An arenaviral immunotherapy targeting cytomegalovirus (CMV). Currently in clinical development. Competitors include Moderna and BioNTech in mRNA-based vaccine approaches.
- HB-700: HB-700 is Hookipau2019s lead oncology candidate, designed to target shared tumor associated antigens, including PRAME and SSX2. Currently in clinical development.
Market Dynamics
Industry Overview
The immunotherapy market is rapidly growing, driven by advancements in cancer and infectious disease treatments. Competition is intense, with numerous companies developing innovative therapies.
Positioning
Hookipa is positioned as an innovator in the viral immunotherapy field, leveraging its arenavirus platform to develop novel treatments.
Total Addressable Market (TAM)
The global immunotherapy market is estimated to be worth billions of dollars. Hookipa is positioned to capture a share of this market with its innovative technologies.
Upturn SWOT Analysis
Strengths
- Proprietary arenavirus platform
- Potential for potent immune responses
- Experienced management team
Weaknesses
- Early-stage clinical development
- Limited financial resources
- Dependence on collaborations
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion into new therapeutic areas
- Positive clinical trial results
Threats
- Competition from established immunotherapy companies
- Regulatory hurdles
- Clinical trial failures
Competitors and Market Share
Key Competitors
- MRNA
- BNTX
- GILD
Competitive Landscape
Hookipa faces significant competition from larger, more established immunotherapy companies. Its competitive advantage lies in its unique arenavirus platform. It is in early stages compared to the others.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by investment in R&D and progress in clinical trials. Revenue is largely dependent on partnership agreements.
Future Projections: Future growth is dependent on clinical trial success and regulatory approvals. Analyst estimates would provide specific projections for revenue and earnings.
Recent Initiatives: Recent initiatives include advancing clinical trials for HB-101 and HB-700 and seeking partnerships to expand development and commercialization efforts.
Summary
Hookipa Pharma is an early-stage biotech company with a novel arenavirus platform for developing immunotherapies. While its technology holds promise, it faces significant challenges due to its limited financial resources and intense competition. Successful clinical trials and strategic partnerships are crucial for its future growth. Investors should be aware of the high risk and potential reward associated with this company. Its AI Rating is low due to these circumstances.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Industry Reports
- Analyst Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be based on individual research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Hookipa Pharma Inc
Exchange NASDAQ | Headquaters New York, NY, United States | ||
IPO Launch date 2019-04-18 | CEO, President & Director Dr. Malte Peters M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 82 | Website https://www.hookipapharma.com |
Full time employees 82 | Website https://www.hookipapharma.com | ||
HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunetherapeutics targeting infectious diseases based on its proprietary arenavirus platform. The company's immuno-oncology pipeline includes HB-700, a novel next-generation multi-KRAS mutant-targeting investigational immunotherapy for the treatment of KRAS mutated cancers, including lung, colorectal, and pancreatic cancers; Eseba-vec, an investigational immunotherapeutic agent in clinical development for the treatment of Human Papillomavirus 16-positive (HPV16+) head and neck cancers with enrollment completed in a Phase 1/2 clinical trial; and HB-300, which targets self-antigens for the treatment of prostate cancer. It is also developing HB-400 for the treatment of Hepatitis B that is in Phase I of clinical trial; and HB-500 for the treatment of Human Immunodeficiency Virus (HIV) that is in Phase I of clinical trial. The company has a collaboration and license agreement with Gilead Sciences, Inc. to collaborate on preclinical research programs to evaluate potential vaccine products for the treatment, cure, diagnosis, or prevention of the hepatitis B virus (HBV) and the HIV. HOOKIPA Pharma Inc. was incorporated in 2011 and is headquartered in New York, New York.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.